| 2017-12-07 14:36:44|
SAGE 14:36 12/07 12/07/17
Sage Therapeutics price target raised to $225 from $140 at Chardan
Chardan analyst Gbola Amusa raised his price target for Sage Therapeutics to $225 cting the positive top-line results from the Phase II trial of SAGE-217 in moderate-to-severe major depressive disorder. Importantly, the beneficial effects of SAGE-217 were reported as soon as the morning following the first dose, the analyst tells investors in a research note. He believes this further demonstrates the "rapid effect" of SAGE-217 compared to standard treatments for major depressive disorder. He sees the data as a "step in the direction of blockbuster sales" and keeps a Buy rating on Sage.